Disclosed are compound exhibiting highly active and selective binding to ανβ6 integrin, which are represented by the following general formula (I): Cyclo-( Arg-X 1 - Asp-X2-X3-X4-X5-X6-X7) (I) wherein the variables groups X to X have the following meanings X1 : Ser, Gly, Thr, X2: Leu, lie, Nle, Val, Phe, X3: Gly, Ala, X4: Leu, He, Nle, Val, Phe, Lys, Tyr, Trp, Arg, X5: D-Pro, N-Me-D-lipophilic amino acids, X6: Pro, N-Me-amino acids, N-Me-Lys, N-Me-Lys(Ac), and X7； Ala, Leu, He, Nle, Val, Phe, Tyr, Trp or wherein the sub-sequence -X5-X6- represents a β-turn mimetic differing from the meanings above, or pharmaceutically acceptable salts, esters, solvates, polymorphs or modified forms thereof represented by the following general formula (II): (X0)n1L(X8)n2 wherein X° represents the compound of the general formula (I) as specified above (excluding one hydrogen atom to allow bonding to the linker), L represents a linker, X8 represents the effector moiety and wherein n1 and n2 are each independently selected from the range of 1 to 5, wherein n1 +n2 represents the number of valencies of the linker and is preferably in the range of from 2 to 6, more preferably 3-5, with the proviso that each of n1 and n2 is at least 1, as well as uses therefore in therapy and imaging.L'invention concerne des composés présentant une liaison hautement active et sélective pour l'intégrine ανβ6, qui sont représentés par la formule générale suivante (I) : Cyclo-( Arg-X 1 - Asp-X2-X3-X4-X5-X6-X7) (I) dans laquelle les groupes variables X à X ont les significations suivantes X1 : Ser, Gly, Thr, X2 : Leu, lie, Nle, Val, Phe, X3 : Gly, Ala, X4 : Leu, He, Nle, Val, Phe, Lys, Tyr, Trp, Arg, X5 : acides aminés lipophiles D-Pro, n-Me-D, X6 : acides aminés Pro, n-Me, n-Me-Lys, n-Me-Lys (Ac), et X7, Ala, Leu, He, Nle, Val, Phe, Tyr, Trp ou dans laquelle la sous-séquence-X5-X6-représente un mimétique à spire bêta différent des significations ci-dessus, ou des sels, esters, solvates, polymorphes ou formes m
